Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 18,603 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Phase 1 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment

NCT03983161
View directory record Official record
Conditions
Healthy Volunteers, Hepatic Impairment
Interventions
Fedratinib
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 23, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

NCT02161770
View directory record Official record
Conditions
Solid Tumours
Interventions
AZD9291 tablet dosing, Pharmacokinetic sampling - AZD9291, Pharmacokinetic sampling - AZ5140 and AZ7550
Drug · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
San Diego, California • Atlanta, Georgia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 23, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing The Effects Of Epoetin Hospira Single-Dose Vial (SDV) And Multi-Dose Vial (MDV) When Administered Subcutaneously To Normal Healthy Subjects

NCT03398473
View directory record Official record
Conditions
Healthy
Interventions
Epoetin Hospira SDV, Epoetin Hospira MDV
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 23, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male Subjects

NCT03641573
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[14C] ASN002
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
20 Years to 60 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 23, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY3039478 in Participants With Advanced Cancer

NCT01695005
View directory record Official record
Conditions
Neoplasms, Neoplasm Metastasis, Lymphoma
Interventions
LY3039478, Prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 23, 2026, 9:10 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

NCT04895722
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Pembrolizumab, Pembrolizumab/Quavonlimab, Pembrolizumab/Favezelimab, Pembrolizumab/Vibostolimab, MK-4830
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Orange City, Florida • Athens, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 23, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

NCT01462851
View directory record Official record
Conditions
Healthy
Interventions
PF-05297909 25 mg, PF-05297909 100 mg, PF-05297909 250 mg, PF-05297909 525 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Glendale, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 23, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy

NCT01998529
View directory record Official record
Conditions
Lung Cancer
Interventions
Cisplatin, Amifostine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 23, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

NCT04040231
View directory record Official record
Conditions
Mesothelioma, Pleural Mesothelioma, Wilms Tumor
Interventions
Galinpepimut-S, Nivolumab, Sargramostim
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 23, 2026, 9:10 AM EDT
Terminated Phase 1 Interventional

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

NCT04956302
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Panobinostat Lactate
Drug
Lead sponsor
Abdullah Khan
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 23, 2026, 9:10 AM EDT
Suspended Phase 1 Interventional

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

NCT05685602
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Emavusertib, Gemcitabine Hydrochloride, Nab-paclitaxel
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Duarte, California • Irvine, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function

NCT06048302
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
Obicetrapib
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Saint Paul, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Results available

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)

NCT00891202
View directory record Official record
Conditions
Gaucher Disease, Type 1
Interventions
Eliglustat tartrate, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
16 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
6
States / cities
San Francisco, California • New Haven, Connecticut • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 23, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects

NCT04211545
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Rabeprazole, CC-92480
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 23, 2026, 9:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

NCT06803875
View directory record Official record
Conditions
Relapsed Neuroblastoma, Refractory Neuroblastoma, High-risk Neuroblastoma
Interventions
Autologous hALK.CAR T cells
Biological
Lead sponsor
Roberto Chiarle
Other
Eligibility
12 Months to 29 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 23, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02

NCT03776539
View directory record Official record
Conditions
Impaired Renal Function
Interventions
ELX-02
Drug
Lead sponsor
Eloxx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 23, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants

NCT07020988
View directory record Official record
Conditions
Healthy Participants
Interventions
Staccato Alprazolam, Midazolam, Diazepam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
20 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 23, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

NCT03262103
View directory record Official record
Conditions
Prostate Cancer
Interventions
Intratumoral (IT) Poly ICLC 0.5 mg, Intratumoral (IT) Poly ICLC 1.0 mg, Intramuscular (IM) Poly ICLC, Radical Prostatectomy
Biological · Procedure
Lead sponsor
Ashutosh Kumar Tewari
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 23, 2026, 9:10 AM EDT
Completed No phase listed Observational

Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel

NCT00003569
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
Interventions
cisplatin, dimesna, paclitaxel
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 23, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Results available

SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors

NCT01661283
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma
Interventions
everolimus, bevacizumab
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 23, 2026, 9:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

Lead-212 PSV359 Therapy for Patients With Solid Tumors

NCT06710756
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma
Interventions
[203Pb]Pb-PSV359, [212Pb]Pb-PSV359
Drug
Lead sponsor
Perspective Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
16
States / cities
Los Angeles, California • Miami, Florida • Kansas City, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants

NCT06746402
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986278, Placebo, Moxifloxacin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 23, 2026, 9:10 AM EDT
Completed Phase 1 Interventional

Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT01757639
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Ipilimumab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
9
States / cities
New Haven, Connecticut • North Haven, Connecticut • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 23, 2026, 9:10 AM EDT
Completed Phase 2 Interventional

SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

NCT00002657
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bleomycin sulfate, recombinant interferon alfa, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methotrexate, prednisone, vincristine sulfate, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
15 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2011
U.S. locations
86
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 23, 2026, 9:10 AM EDT